Jazz’s Vyxeos rollout hit a wall in Q3. What’s the holdup?

Jazz Pharmaceuticals has a couple of new selling points—and a bigger supporting salesforce—for its leukemia drug Vyxeos, so why did sales fall so far short of expectations in the third quarter? Because it’s facing some new barriers to access, too.